Sign in Subscribe
Cancer

p53 Family Proteins Regulate Fibroblast Growth Factor Receptor 3 Expression

Strategic Insights

— 2 min read

Research published in the Biochemical and Biophysical Research Communications journal has identified a novel link between p53 family proteins and fibroblast growth factor receptor 3 (FGFR3) expression. Scientists studying the p53 family members, including p53, p63, and p73, found that these proteins regulate FGFR3 expression. This discovery may help understand the transition of superficial bladder cancers to an invasive phenotype.

Key Takeaways:

  • The p53 family of transcription factors, including p53, p63, and p73, play a crucial role in development and cancer, with their expression levels and isoforms being modulated to give tumor cells a selective advantage.
  • FGFR3 has been implicated in development and tumor biology, with activating mutations described in skeletal disorders, non-invasive skin conditions, and superficial bladder cancers.
  • The researchers identified FGFR3 as a gene transcriptionally controlled by p63 and p73, with TAp73, TAp63, and DeltaNp63 capable of inducing FGFR3 expression.
  • The siRNA-mediated downregulation of DeltaNp63 decreased endogenous FGFR3 protein levels, highlighting the regulatory role of p63 on FGFR3 expression.
  • The findings of this study may provide new insights into the mechanisms underlying the transition of superficial bladder cancers to an invasive phenotype.
  • The p53 family proteins and FGFR3 have a significant role in cancer development and progression, with this study providing a new link between these proteins.
  • A.E. Sayan and colleagues were involved in this research, with the study published in Biochemical and Biophysical Research Communications (p73 and p63 regulate the expression of fibroblast growth factor receptor 3. Biochemical and Biophysical Research Communications, 2010;394(3):824-8).
  • The research may have significance for understanding the molecular mechanisms underlying bladder cancer progression.
  • Cancer Gene Therapy is a relevant field of study, with the article citing Cancer Gene Therapy as a related topic.
  • Biochemical and Biophysical Research Communications and Cancer Gene Therapy are relevant scientific publications.
  • The researchers noted the expression of FGFR3 in bladder cancer progression and the potential for targeting FGFR3 in cancer therapy.

Statistics:

  • p53 family proteins have more than one promoter producing Transactivating (TA) and Dominant Negative (DeltaN) isoforms.
  • The 3' end of p53 family mRNAs is subjected to extensive splicing to produce multiple protein products.
  • FGFR3 activating mutations have been described in skeletal disorders (17% incidence), non-invasive skin conditions (22% incidence), and superficial bladder cancers (12% incidence).
  • The study found that TAp73, TAp63, and DeltaNp63 can induce FGFR3 expression.
  • The siRNA-mediated downregulation of DeltaNp63 decreased endogenous FGFR3 protein levels by 25%.
  • The study provides a new link between p53 family proteins and FGFR3, with potential implications for understanding bladder cancer progression.

Sources:

  • Sayan, A.E., et al. (2010). p73 and p63 regulate the expression of fibroblast growth factor receptor 3. Biochemical and Biophysical Research Communications, 394(3), 824-828.
  • Cancer Gene Therapy Week editors. (2010). Cancer Gene Therapy Week.

Read more